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ABSTRACTS S235Conclusion: NGS liquid biopsy analysis has a big validity either for
mutation detection at the time of diagnosis or for the detection of early mo-
lecular relapse following treatment.
http://dx.doi.org/10.1016/j.ejso.2016.07.074
191. Malignant bowel obstruction e How can we do better?
Sarah Slater, Ros Glasspool, Stephen McKay, Helen MacKay, Nicky
Donnelly, Alison Mitchell, Doherty Graeme
Beatson West of Scotland Cancer Centre, UK
Background: Malignant small bowel obstruction (SBO) affects
20e50% of ovarian cancer patients and has a grave prognosis (Caprotti
et al, 2006). There is little evidence to guide optimal management of these
patients and they often require prolonged periods in hospital. Surgery is
rarely an option as ovarian cancer SBO is characteristically multi-focal.
Medical management includes a combination of opioids, antiemetics, glu-
cocorticoids and antisecretory drugs with limited symptomatic response
rates. Research suggests that a subpopulation of patients benefit from early
intervention with total parenteral nutrition (TPN) and chemotherapy (Abu-
Rustum et al, 1997; Bryan, 2006) but there are currently no established
prognostic indicators to identify those patients most likely to benefit
from TPN and access to home TPN varies around the country.
In December 2015 Health Improvement Scotland published Complex
Nutritional Care Standards which require that NHS boards ensure patients
are considered for complex nutritional care by a multidisciplinary team
(MDT). At the Beatson, West of Scotland Cancer Centre (BWSCC), we
have established a MDT to develop new guidelines and pathways for the
management of patients with malignant SBO.
Method: To inform this process we undertook a retrospective study of
current practice and outcomes in ovarian cancer patients with SBO at
BWoSCC admitted over two years.
Results: We present data on 56 patient admissions, including age, per-
formance status, BMI, stage of disease, presence of ascites, previous and
current anti-cancer therapy, laboratory factors including, albumin, white
cell count and CA-125 were recorded as well as data on length of stays,
use and complications of TPN, resolution of obstruction, place of discharge
and survival. The current inpatient journey, specifically referral processes to
dieticians, TPN team, surgeons and palliative care team is reviewed.
Conclusion: The necessity for a MDT in complex nutrition care of
cancer patients is demonstrated.
http://dx.doi.org/10.1016/j.ejso.2016.07.075
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stereotactic prostate radiotherapy in high-risk localised prostate
cancer with or without elective nodal irradiation
Ciara Lyons1, ConorMcGarry2, Alan Hounsell2, SharonHynds2, Kevin
Prise3, Joe O’Sullivan3, Suneil Jain3
1 Centre for Cancer Research and Cell Biology, UK
2Northern Ireland Cancer Centre, Belfast Health and Social Care Trust,
UK
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Background: Prostate Cancer (PC) has a low alpha-beta ratio, making
it sensitive to hypofractionated radiotherapy. Stereotactic ablative radio-
therapy (SABR) provides an opportunity for dose escalation beyond that
achievable with conventional radiotherapy. Additionally, there is a lack
of novel biomarkers in use in the management of localized PC.
Method: Thirty men with high-risk node-negative PC (at least one
of PSA > 20 ng/mL, T3a, Gleason score  4 + 3) will be randomized
on a 1:1 basis to receive SABR to the prostate (P) and proximal sem-
inal vesicles (SV) alone (36.25 Gy/5#) or to the addition of electivepelvic nodal irradiation (ENI) (25 Gy/5#). All men will be treated us-
ing a volumetric arc therapy solution with intra-prostatic fiducial
markers, a prostate-rectal spacer device and cone-beam CT-based im-
age-guidance.
Results: The primary objective of this study is to demonstrate the
feasibility of performing a randomised trial comparing P/SV SABR to
the addition of ENI SABR in men with high-risk localised PC. This
will be measured via distinct endpoints: adequate recruitment rate (30 pa-
tients in 24 months), number of plans delivered as planned and on
schedule, and quantification of acute toxicity to enable calculation of
the sample size for a subsequent Phase II trial (CTCAE v4.03). Secondary
objectives include quantification of late toxicity and quality of life scores
and assessment of PC outcomes post-SABR. Tertiary and exploratory out-
comes include the biobanking of clinically annotated tissue, a health eco-
nomic analysis, assessment of multiple biomarker candidates,
measurement of fatigue, and assessment of the impact of prostate spacer
placement.
Conclusion: SABR provides scope for dose escalation in men with
high-risk localized PC. The role of ENI has not been determined. Further-
more, this trial offers an additional opportunity for novel biomarker inves-
tigation in localized PC.
http://dx.doi.org/10.1016/j.ejso.2016.07.076
207. The extent and impact of musculoskeletal dysfunction on women
following breast reconstruction using the latissimus dorsi muscle: A
questionnaire survey
Nicole Blackburn, Iseult Wilson, Joseph McVeigh, Eilis McCaughan
Ulster University, UK
Background: Quality of life is becoming more important in regard
to breast cancer as treatment advances extend the period of survivor-
ship. Breast reconstruction following mastectomy is an important man-
agement option in breast cancer, therefore the functional implications
associated with this surgery must be considered. The latissimus dorsi
(LD) flap is one the most widely used surgical procedures for women
with breast cancer undergoing reconstructive surgery. To date, literature
has mainly focused on body image and wound healing with little in-
depth investigation of the impact of this surgery on shoulder function.
Few studies have specifically investigated the musculoskeletal impact
of surgery and of those that have, findings have varied regarding the
impact and extent.
Method: A postal survey design was used to gather detailed and per-
sonal information from women who had LD breast reconstruction. All
eligible women who underwent LD flap surgery through the Northern
Ireland Health and Social Care Trusts were included in the study. A range
of validated outcome measures were included in order to determine both
the physical and psychosocial implications of LD breast reconstruction
in women following mastectomy for breast cancer.
Results: A total of 159 women, (mean age ¼ 46.8  7.9 years; mean
time since surgery ¼ 4.3  2.9 years) completed the survey. The results
from the validated outcome measure scores demonstrated low to moderate
dysfunction among the group. Subgroup analysis revealed that auxiliary
node removal significantly impacted disability scores (p ¼ .036) as per
DASH and quality of life scores regarding mobility (p ¼ .008) and self-
care (p ¼ .030) as per EuroQol.
Conclusion: The findings from this study indicate that LD breast
reconstruction has an impact on the functional ability of patients undergo-
ing this specific procedure, with the results from the validated outcome
measure scores demonstrating low to moderate dysfunction among the
group.
http://dx.doi.org/10.1016/j.ejso.2016.07.077
